ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,821Medicare Part D Prescriptions Filled, Including Refills

Rank: 350 out of 1677

$443K Total Retail Price of All Prescriptions

Rank: 433 out of 1677

623 Patients Receiving at Least One Drug in Part D
54%Patients 65 Years and Older
85% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Georgia
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

19% of this provider’s 623 patients filled at least one prescription for a schedule three drug, compared to an average of 14%.

Risky Drugs to Seniors

1% of this provider’s 5,332 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

24% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$45 was the average price of a prescription from this provider, compared to $53 among peers.

Prescriptions per Patient

16 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Georgia
LISINOPRIL 521 292 1 3
AMLODIPINE BESYLATE 448 304 2 2
SIMVASTATIN 425 250 3 1
METFORMIN HCL 345 172 4 7
HYDROCODONE-ACETAMINOPHEN 280 133 S3 5 4
LEVOTHYROXINE SODIUM 244 136 6 5
HYDROCHLOROTHIAZIDE 207 142 7 9
OMEPRAZOLE 204 81 8 6
METOPROLOL TARTRATE 190 135 9 12
GABAPENTIN 183 91 10 11
PRAVASTATIN SODIUM 175 95 11 10
LISINOPRIL-HYDROCHLOROTHIAZIDE 171 94 12 17
FUROSEMIDE 165 85 13 8
ATENOLOL 158 85 14 21
RANITIDINE HCL 150 85 15 18
NEXIUM 144 62 16 19
INSULIN SYRINGE 138 73 17 72
FAMOTIDINE 136 82 18 41
CITALOPRAM HBR 135 61 19 22
CRESTOR 131 77 20 28
LOVASTATIN 127 75 21 35
TRAMADOL HCL 117 89 22 16
POTASSIUM CHLORIDE 117 68 22 14
ZOLPIDEM TARTRATE 113 57 24 15
FLUTICASONE PROPIONATE 106 41 25 29
CYCLOBENZAPRINE HCL 104 31 R 26 52
METOPROLOL SUCCINATE 102 84 27 23
PROAIR HFA 96 46 28 50
ATORVASTATIN CALCIUM 94 58 29 13
MELOXICAM 94 42 29 27
TRAZODONE HCL 93 22 31 37
FENOFIBRATE 87 36 32 48
GLIPIZIDE 84 56 33 56
CLONIDINE HCL 82 32 34 36
ALLOPURINOL 72 56 35 31
LOSARTAN POTASSIUM 67 42 36 25
WARFARIN SODIUM 65 47 37 24
HYDRALAZINE HCL 61 38 38 69
CARVEDILOL 60 34 39 20
SERTRALINE HCL 59 31 40 26
LANTUS 59 18 40 44
VERAPAMIL ER 57 26 42 86
ENALAPRIL MALEATE 57 33 42 82
VENTOLIN HFA 56 20 44 89
GLIMEPIRIDE 54 36 45 33
SPIRIVA 53 15 46 74
TRILIPIX 51 12 47 175
NAPROXEN 51 17 47 87
PHENYTOIN SODIUM EXTENDED 51 0 47 112
COMBIVENT 50 14 50 105
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on April 9, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.